CN111479813B - 作为加压素v1a受体拮抗剂的三唑并苯并吖庚因 - Google Patents
作为加压素v1a受体拮抗剂的三唑并苯并吖庚因 Download PDFInfo
- Publication number
- CN111479813B CN111479813B CN201880080932.8A CN201880080932A CN111479813B CN 111479813 B CN111479813 B CN 111479813B CN 201880080932 A CN201880080932 A CN 201880080932A CN 111479813 B CN111479813 B CN 111479813B
- Authority
- CN
- China
- Prior art keywords
- chloro
- triazolo
- trans
- dihydro
- cyclohexyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP1700521 | 2017-12-15 | ||
| HU1700521A HU231206B1 (hu) | 2017-12-15 | 2017-12-15 | Triazolobenzazepinek |
| PCT/IB2018/060077 WO2019116324A1 (en) | 2017-12-15 | 2018-12-14 | Triazolobenzazepines as vasopressin v1a receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111479813A CN111479813A (zh) | 2020-07-31 |
| CN111479813B true CN111479813B (zh) | 2023-03-21 |
Family
ID=89992589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880080932.8A Active CN111479813B (zh) | 2017-12-15 | 2018-12-14 | 作为加压素v1a受体拮抗剂的三唑并苯并吖庚因 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11298363B2 (https=) |
| EP (1) | EP3724192B1 (https=) |
| JP (1) | JP7428647B2 (https=) |
| KR (1) | KR102719165B1 (https=) |
| CN (1) | CN111479813B (https=) |
| AR (1) | AR113933A1 (https=) |
| AU (1) | AU2018385724B2 (https=) |
| BR (1) | BR112020011880A2 (https=) |
| CA (1) | CA3085562A1 (https=) |
| CL (1) | CL2020001564A1 (https=) |
| CU (1) | CU24630B1 (https=) |
| EA (1) | EA202091344A1 (https=) |
| HU (1) | HU231206B1 (https=) |
| IL (1) | IL275084B2 (https=) |
| JO (1) | JOP20200149B1 (https=) |
| MX (1) | MX2020006204A (https=) |
| PE (1) | PE20210671A1 (https=) |
| PH (1) | PH12020500548A1 (https=) |
| SG (1) | SG11202005299VA (https=) |
| TN (1) | TN2020000083A1 (https=) |
| TW (1) | TWI826406B (https=) |
| UA (1) | UA129516C2 (https=) |
| WO (1) | WO2019116324A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI901650B (zh) | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| WO2022018121A1 (en) * | 2020-07-23 | 2022-01-27 | F. Hoffmann-La Roche Ag | Cyclohexyl substituted triazoles as vasopressin receptor v1 a antagonists |
| TWI804119B (zh) * | 2020-12-21 | 2023-06-01 | 大陸商上海濟煜醫藥科技有限公司 | 三氮唑類三并環衍生物及其製備方法和應用 |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| WO2023164710A1 (en) * | 2022-02-28 | 2023-08-31 | The Trustees Of Columbia University In The City Of New York | Avpr1a blockade to reduce social isolation-induced anxiety in females |
| US12310974B1 (en) | 2023-12-19 | 2025-05-27 | Samuel Aballea | Method of treating post-traumatic stress disorder with carpipramine |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004074291A1 (en) * | 2003-02-19 | 2004-09-02 | Pfizer Limited | Triazole compounds useful in therapy |
| WO2005068466A1 (en) * | 2004-01-13 | 2005-07-28 | Pfizer Limited | Compounds useful in therapy |
| WO2006021882A1 (en) * | 2004-08-25 | 2006-03-02 | Pfizer Limited | Triazolobenzodiazepines and their use as vasopressin antagonists |
| WO2008052628A1 (de) * | 2006-11-03 | 2008-05-08 | Merck Patent Gmbh | Triaza-benzo[e]azulenderivate zur behandlung von tumoren |
| WO2011131596A1 (en) * | 2010-04-21 | 2011-10-27 | F. Hoffmann-La Roche Ag | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes as vasopressin v1a receptor antagonists |
| CN103327980A (zh) * | 2010-11-15 | 2013-09-25 | 艾吉因生物股份有限公司 | 用于治疗认知障碍的苯并二吖庚因衍生物、组合物和方法 |
| WO2014048945A1 (de) * | 2012-09-28 | 2014-04-03 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische 5-aryl-triazolo-azepine |
| CN106349241A (zh) * | 2015-07-15 | 2017-01-25 | 上海翰森生物医药科技有限公司 | 具有hsp90抑制活性的三唑衍生物及其制备方法和应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0382185B1 (en) | 1989-02-10 | 1994-06-15 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| FR2679903B1 (fr) | 1991-08-02 | 1993-12-03 | Elf Sanofi | Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant. |
| EP1097920B1 (en) | 1993-07-21 | 2004-09-22 | Yamanouchi Pharmaceutical Co. Ltd. | Intermediate for condensed benzazepine derivatives |
| ES2284741T3 (es) | 1994-06-15 | 2007-11-16 | Otsuka Pharmaceutical Company, Limited | Derivados de benzoheterociclicos utilizados como moduladores de vasoprsinao de oxitocina. |
| FR2740136B1 (fr) | 1995-10-24 | 1998-01-09 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant |
| SK16242002A3 (sk) | 2000-05-19 | 2003-04-01 | Merck Patent Gmbh | Derivát triazolu a farmaceutický prostriedok, ktorý ho obsahuje |
| US7001898B2 (en) | 2000-07-05 | 2006-02-21 | Ortho-Mcneil Pharmaceutical, Inc. | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists |
| US7056910B2 (en) | 2000-11-28 | 2006-06-06 | Astellas Pharma Inc. | 1,4,5.6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof |
| MXPA04003358A (es) | 2001-10-12 | 2004-07-08 | Serenix Pharmaceuticals Llc | Antagonistas de vasopresina v1a de ?-lactamilo. |
| JP2005104838A (ja) | 2003-01-09 | 2005-04-21 | Tanabe Seiyaku Co Ltd | 縮合フラン化合物 |
| KR100750028B1 (ko) * | 2003-02-19 | 2007-08-16 | 화이자 인코포레이티드 | 치료에 유용한 트리아졸 화합물 |
| GB0325021D0 (en) * | 2003-10-27 | 2003-12-03 | Pfizer Ltd | Therapeutic combinations |
| EA010132B1 (ru) | 2003-12-22 | 2008-06-30 | Пфайзер Инк. | Производные триазола в качестве антагонистов вазопрессина |
| EP1632494A1 (en) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
| CA2593044A1 (en) | 2004-12-31 | 2006-07-13 | Abbott Gmbh & Co. Kg | Substituted oxindole derivatives, medicaments containing said derivatives and use thereof |
| CA2602194A1 (en) | 2005-03-24 | 2006-09-28 | Abbott Gmbh & Co. Kg | Substituted oxindol derivatives, drugs containing said derivatives and the use thereof |
| ES2434467T3 (es) | 2005-05-13 | 2013-12-16 | Lexicon Pharmaceuticals, Inc. | Compuestos multicíclicos y métodos para su uso |
| CA2615726C (en) | 2005-07-14 | 2014-05-27 | Caterina Bissantz | Indol-3-yl-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists |
| KR100984893B1 (ko) | 2005-07-21 | 2010-10-01 | 에프. 호프만-라 로슈 아게 | Ｖ1ａ 수용체 길항제로서의인돌-3-일-카보닐-피페리딘-벤조이미다졸 유도체 |
| EP2392571A3 (en) | 2005-07-29 | 2012-03-14 | F. Hoffmann-La Roche AG | Indol-3-yl-carbonyl-piperidin and piperazin derivatives |
| JP2010517966A (ja) | 2007-02-01 | 2010-05-27 | グラクソ グループ リミテッド | 摂食障害の処置のための１−オキサ−３−アザスピロ（４．５）デカン−２−オンおよび１−オキサ−３，８−ジアザスピロ（４．５）デカン−２−オン誘導体 |
| TWI459947B (zh) | 2007-06-26 | 2014-11-11 | Otsuka Pharma Co Ltd | 苯并氮呯化合物及藥學製劑 |
| BRPI0922303B1 (pt) | 2008-11-28 | 2019-11-12 | Hoffmann La Roche | arilciclo-hexiléteres de di-hidrotetra-azabenzoazulenos, seu processo de preparação, composição farmacêutica que os compreende e uso |
| GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
| TW201103907A (en) | 2009-03-20 | 2011-02-01 | Lundbeck & Co As H | Amide derivatives as neuropeptide Y5 receptor ligands |
| SG10201406839VA (en) | 2009-10-26 | 2014-12-30 | Otsuka Pharma Co Ltd | Benzazepine compound |
| GB201004677D0 (en) | 2010-03-19 | 2010-05-05 | Vantia Ltd | New salt |
| US8461151B2 (en) | 2010-04-13 | 2013-06-11 | Hoffmann-La Roche Inc. | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes |
| US8513238B2 (en) | 2010-05-10 | 2013-08-20 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes |
| EP2569280B1 (en) | 2010-05-11 | 2015-02-25 | Sanofi | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof |
| CN105263910A (zh) | 2013-02-18 | 2016-01-20 | 斯克利普斯研究所 | 具有治疗潜力的血管加压素受体调节剂 |
| EP3230281B1 (en) | 2014-12-09 | 2021-05-26 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
| RU2017131562A (ru) | 2015-02-27 | 2019-03-27 | Версеон Корпорейшн | Замещенные пиразольные соединения как ингибиторы сериновых протеаз |
| WO2017007756A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc | Hetero-halo inhibitors of histone deacetylase |
| US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
| AR108263A1 (es) | 2016-05-03 | 2018-08-01 | Bayer Pharma AG | Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo |
| EP3452472A1 (en) | 2016-05-03 | 2019-03-13 | Bayer Aktiengesellschaft | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof |
-
2017
- 2017-12-15 HU HU1700521A patent/HU231206B1/hu unknown
-
2018
- 2018-12-12 TW TW107144774A patent/TWI826406B/zh active
- 2018-12-13 AR ARP180103643A patent/AR113933A1/es unknown
- 2018-12-14 JO JOP/2020/0149A patent/JOP20200149B1/ar active
- 2018-12-14 EA EA202091344A patent/EA202091344A1/ru unknown
- 2018-12-14 SG SG11202005299VA patent/SG11202005299VA/en unknown
- 2018-12-14 KR KR1020207020172A patent/KR102719165B1/ko active Active
- 2018-12-14 UA UAA202004230A patent/UA129516C2/uk unknown
- 2018-12-14 TN TNP/2020/000083A patent/TN2020000083A1/en unknown
- 2018-12-14 US US16/954,085 patent/US11298363B2/en active Active
- 2018-12-14 EP EP18836400.4A patent/EP3724192B1/en active Active
- 2018-12-14 PE PE2020000640A patent/PE20210671A1/es unknown
- 2018-12-14 JP JP2020532928A patent/JP7428647B2/ja active Active
- 2018-12-14 WO PCT/IB2018/060077 patent/WO2019116324A1/en not_active Ceased
- 2018-12-14 CN CN201880080932.8A patent/CN111479813B/zh active Active
- 2018-12-14 BR BR112020011880-0A patent/BR112020011880A2/pt unknown
- 2018-12-14 CU CU2020000048A patent/CU24630B1/es unknown
- 2018-12-14 AU AU2018385724A patent/AU2018385724B2/en active Active
- 2018-12-14 CA CA3085562A patent/CA3085562A1/en active Pending
- 2018-12-14 MX MX2020006204A patent/MX2020006204A/es unknown
-
2020
- 2020-06-03 IL IL275084A patent/IL275084B2/en unknown
- 2020-06-09 PH PH12020500548A patent/PH12020500548A1/en unknown
- 2020-06-11 CL CL2020001564A patent/CL2020001564A1/es unknown
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004074291A1 (en) * | 2003-02-19 | 2004-09-02 | Pfizer Limited | Triazole compounds useful in therapy |
| WO2005068466A1 (en) * | 2004-01-13 | 2005-07-28 | Pfizer Limited | Compounds useful in therapy |
| WO2006021882A1 (en) * | 2004-08-25 | 2006-03-02 | Pfizer Limited | Triazolobenzodiazepines and their use as vasopressin antagonists |
| WO2008052628A1 (de) * | 2006-11-03 | 2008-05-08 | Merck Patent Gmbh | Triaza-benzo[e]azulenderivate zur behandlung von tumoren |
| WO2011131596A1 (en) * | 2010-04-21 | 2011-10-27 | F. Hoffmann-La Roche Ag | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes as vasopressin v1a receptor antagonists |
| CN103327980A (zh) * | 2010-11-15 | 2013-09-25 | 艾吉因生物股份有限公司 | 用于治疗认知障碍的苯并二吖庚因衍生物、组合物和方法 |
| WO2014048945A1 (de) * | 2012-09-28 | 2014-04-03 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische 5-aryl-triazolo-azepine |
| CN106349241A (zh) * | 2015-07-15 | 2017-01-25 | 上海翰森生物医药科技有限公司 | 具有hsp90抑制活性的三唑衍生物及其制备方法和应用 |
Non-Patent Citations (2)
| Title |
|---|
| Ketenylidenetriphenylphosphorane;Hans Jurgen Bestmann et al.;《Encyclopedia of Reagents for Organic Synthesis》;20110315;第1-7页 * |
| 静脉滴注药物说明书有关稀释程度情况的调查与分析;钟智 等;《食品药品监管》;20111231;第20卷(第14期);第5-6页 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111479813B (zh) | 作为加压素v1a受体拮抗剂的三唑并苯并吖庚因 | |
| DK3344616T3 (en) | SUBSTITUTED AMINOTRIAZOLES USED AS HUMAN CHITINASE INHIBITORS | |
| KR20190012167A (ko) | 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도 | |
| CN111867585A (zh) | 噁二唑瞬时受体电位通道抑制剂 | |
| TW201609751A (zh) | 雜環化合物 | |
| CN102317270A (zh) | 异*唑-异*唑和异*唑-异噻唑衍生物 | |
| TW201132642A (en) | Diaza-spiro[5.5]undecanes | |
| TW201311674A (zh) | 吲唑－及吡咯并吡啶－衍生物及其醫藥用途 | |
| JP2020505399A (ja) | 化合物 | |
| BR112019015314A2 (pt) | compostos para inibir a atividade da quinase lrrk2 | |
| CN101346377A (zh) | 芳基-异噁唑-4-基-咪唑并[1,5-a]吡啶衍生物 | |
| TW201938171A (zh) | 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物 | |
| CN112313220B (zh) | Pd-l1拮抗剂化合物 | |
| CN105793266B (zh) | 螺-噁唑酮 | |
| CN103261190A (zh) | 新苯并呋喃化合物 | |
| WO2021009209A1 (en) | Substituted amino triazoles useful as chitinase inhibitors | |
| CN115461337A (zh) | 作为GABA A α5 PAM的新型三唑基衍生物 | |
| CN102282139A (zh) | 作为nk3受体拮抗剂的哌啶衍生物 | |
| JPWO2007007890A1 (ja) | Ｎ−ジヒドロキシアルキル置換２−オキソイミダゾール誘導体 | |
| EA042383B1 (ru) | Триазолобензазепины как антагонисты v1a рецепторов вазопрессина | |
| OA19571A (en) | Triazolobenzazepines as vasopressin V1a receptor antagonists. | |
| BR112015026514B1 (pt) | Composto triazólico tricíclico, uso do composto, processo para a preparação de compostos, e, composição farmacêutica | |
| CN118974038A (zh) | 杂环化合物和使用方法 | |
| BR112018004193B1 (pt) | Amino triazóis substituídos, seu uso e composição farmacêutica que os compreende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |